Integrating economic analysis into clinical trials

Lancet

Volumn 365, Issue 9473, 2005, Pages 1749-1750

  Imai, Kumiko ^a   Zhang, Ping ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN;

CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DIABETES MELLITUS; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE POLICY; HOSPITALIZATION; HUMAN; INDUSTRIALIZATION; METHODOLOGY; NOTE; OUTPATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REIMBURSEMENT; VASCULAR DISEASE;

EID: 19744374495     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)66390-8     Document Type: Note

References (11)

1. RS Taylor, MF Drummond, G Salkeld, SD Sullivan Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle BMJ 329 2004 972 975
2. UCLA Stroke/Vascular Neurology Program Frequently asked questions http://strokeprotect.mednet.ucla.edu/faq.htm 2002 (accessed April 13, 2005)
3. Diabetes Prevention Program Research Group Costs associated with the primary prevention of type 2 diabetes mellitus in the Diabetes Prevention Program Diabetes Care 26 2003 36 47
4. The Diabetes Prevention Program Research Group Within-trial cost effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes Diabetes Care 26 2003 2518 2523
5. MF Drummond, B O'Brien, GL Stoddart, GW Torrance Methods for the economic evaluation of health care programmes 2nd edn. 1997 Oxford University Press Oxford
6. WH Herman, TJ Hoerger, M Brandle The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance Ann Intern Med 142 2005 323 332
7. MR Gold, JE Siegel, LB Russell, MC Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York
8. AK O'Sullivan, D Thompson, MF Drummond Collection of health economic data alongside clinical trials: is there a future for piggy-back evaluations? Value Health 8 2005 67 79
9. SD Ramsey, M McIntosh, SD Sullivan Design issues for conducting cost effectiveness analyses alongside clinical trials Annu Rev Public Health 22 2001 129 141
10. B O'Brien Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials? Medical Care 34 suppl 1996 DS99 DS108
11. CJL Murray, DB Evans, A Acharya, RMPM Baltussen Development of WHO guidelines on generalized cost-effectiveness analysis Health Econ 9 2000 235 251